JERSEY CITY, N.J., Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. ("60P"), (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its public offering of 5,260,901 units (the "Units") at a price to the public of $0.385 per Unit and 999,076 pre‑funded units (the "Pre‑Funded Units") at a price to the public of $0.375 per Pre‑Funded Unit. The closing of the offering is expected to occur on or about January 31, 2024, subject to the satisfaction of customary closing conditions.
The underwriters have been granted an option, exercisable within 45 days after the closing of this offering, to purchase shares of 60P's common stock at a price of $0.385 per share and/or Warrants at a price of $0.01 per Warrant and/or Pre-Funded Warrants at a price of $0.375 per Pre-Funded Warrant, or any combination of additional shares of common stock, Warrants and/or Pre-Funded Warrants, representing, in the aggregate, up to 15% of the number of Units sold in this offering, 15% of the Warrants underlying the Units and Pre-Funded Units sold in this offering and 15% of the Pre-Funded Warrants underlying the Pre-Funded Units sold in this offering, in all cases less the underwriting discount to cover over-allotments, if any.
WallachBeth Capital is the Sole Bookrunner for the Offering
The offering is being conducted pursuant to 60P's registration statement on Form S‑1 (File No. 333‑276641) previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on January 24, 2024. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from WallachBeth Capital LLC, via email: cap‑This email address is being protected from spambots. You need JavaScript enabled to view it., or by calling +1 (646) 237‑8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.
About WallachBeth Capital LLC
WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. The firm's website is located at www.wallachbeth.com.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release may include forward-looking statements, including statements of future expectations regarding the business and offering of 60P's units. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. We undertake no obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Last Trade: | US$0.90 |
Daily Change: | -0.05 -5.58 |
Daily Volume: | 49,352 |
Market Cap: | US$1.590M |
November 14, 2024 September 06, 2024 September 04, 2024 August 14, 2024 August 12, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB